- Smith, C.A., Farrah, T. & Goodwin, R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76, 959–962 (1994).
Article CAS Google Scholar
- Cosman, D. A family of ligands for the TNF receptor superfamily. Stem Cells 12, 440–455 (1994).
Article CAS Google Scholar
- Armitage, R.J. Tumor necrosis factor receptor superfamily members and their ligands. Curr. Opin. Immunol. 6, 407–413 (1994).
Article CAS Google Scholar
- Peter, M.E., Ehret, A., Berndt, C. & Krammer, P.H. AIDS and the death receptors. Br. Med. Bull. 53, 604– 616 (1997).
Article CAS Google Scholar
- Cohen, J. Cytokines as mediators of graft–versus–host disease. Bone Marrow Transplant. 3, 193–197 (1988).
CAS PubMed Google Scholar
- Fisher, G.H. et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81, 935–946 (1995).
Article CAS Google Scholar
- Wiley, S.R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673–682 (1995).
Article CAS Google Scholar
- Griffith, T.S., Chin, W.A., Jackson, G.C., Lynch, D.H. & Kubin, M.Z. Intracellular regulation of TRAIL–induced apoptosis in human melanoma cells. J. Immunol. 161, 2833–2840.
- Pitti, R.M. et al. Induction of apoptosis by Apo–2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687–12690 (1996).
Article CAS Google Scholar
- Mariani, S.M., Matiba, B., Armandola, E.A. & Krammer, P.H. Interleukin 1 β–converting enzyme related proteases/caspases are involved in TRAIL–induced apoptosis of myeloma and leukemia cells. J. Cell. Biol. 137, 221–229 (1997).
Article CAS Google Scholar
- Pan, G. et al. An antagonist decoy receptor and a death domain–containing receptor for TRAIL. Science 277, 815– 818 (1997).
Article CAS Google Scholar
- Pan, G. et al. The receptor for the cytotoxic ligand TRAIL. Science 276, 111–113 (1997).
Article CAS Google Scholar
- Sheridan, J.P. et al. Control of TRAIL–induced apoptosis by a family of signaling and decoy receptors. Science 277, 818– 821 (1997).
Article CAS Google Scholar
- Walczak, H. et al. TRAIL–R2: a novel apoptosis–mediating receptor for TRAIL. EMBO J. 16, 5386– 5397 (1997).
Article CAS Google Scholar
- Degli–Esposti, M.A. et al. Cloning and characterization of TRAIL–R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186, 1165–1170 (1997).
Article Google Scholar
- Degli–Esposti, M.A. et al. The novel receptor TRAIL–R4 induces NF–κB and protects against TRAIL–mediated apoptosis, yet retains an incomplete death domain. Immunity 7, 813– 820 (1997).
Article Google Scholar
- Marsters, S.A. et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7, 1003– 1006 (1997).
Article CAS Google Scholar
- Fanslow, W.C. et al. Structural characteristics of CD40 ligand that determine biological function. Semin. Immunol. 6, 267– 278 (1994).
Article CAS Google Scholar
- Schneider, P. et al. Conversion of membrane–bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187, 1205–1213 (1998).
Article CAS Google Scholar
- Ogasawara, J. et al. Lethal effect of the anti–Fas antibody in mice. Nature 364, 806–809 (1993).
Article CAS Google Scholar
- Tanaka, M., Suda, T., Yatomi, T., Nakamura, N. & Nagata, S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J. Immunol. 158, 2303–2309 (1997).
CAS Google Scholar
- Revel, M. & Schattner, A. Interferons: cytokines in autoimmunity. Ciba. Found. Symp. 129, 223– 233 (1987).
CAS PubMed Google Scholar
- Cerami, A. & Beutler, B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol. Today 9, 28–31 (1988).
Article CAS Google Scholar
- Fiers, W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett. 285, 199– 212 (1991).
Article CAS Google Scholar
- Elliott, M.J. et al. Randomised double–blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105– 1110 (1994).
Article CAS Google Scholar
- Moreland, L.W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)–Fc fusion protein. N. Engl. J. Med. 337, 141–147 (1997).
Article CAS Google Scholar
- Zheng, L.X. et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377, 348– 351 (1995).
Article CAS Google Scholar
- Vandenabeele, P., Declercq, W., Vanhaesebroeck, B., Grooten, J. & Fiers, W. Both TNF receptors are required for TNF–mediated induction of apoptosis in PC60 cells. J. Immunol. 154, 2904–2913 (1995).
CAS PubMed Google Scholar
- Brouckaert, P.G., Leroux–Roels, G.G., Guisez, Y., Tavernier, J. & Fiers, W. In vivo anti–tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN–γ, on a syngeneic murine melanoma. Int. J. Cancer 38, 763–769 (1986).
Article CAS Google Scholar
- Havell, E.A., Fiers, W. & North, R.J. The antitumor function of tumor necrosis factor d(TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J. Exp. Med. 167, 1067–1085 (1988).
Article CAS Google Scholar
- Alderson, M.R. et al. Fas ligand mediates activation–induced cell death in human T lymphocytes. J. Exp. Med. 181, 71–77 (1995).
Article CAS Google Scholar
- Dhein, J., Walczak, H., Bäumler, C., Debatin, K.–M. & Krammer, P.H. Autocrine T–cell suicide mediated by APO–1/(Fas/CD95). Nature 373, 438–441 (1995).
Article CAS Google Scholar
- Brunner, T. et al. Cell–autonomous Fas (CD95)/Fas–ligand interaction mediates activation–induced apoptosis in T–cell hybridomas. Nature 373, 441–444 (1995).
Article CAS Google Scholar
- Ju, S.–T. et al. Fas(CD95)/FasL interactions required for programmed cell death after T–cell activation. Nature 373, 444–448 (1995).
Article CAS Google Scholar
- Lowin, B., Hahne, M., Mattmann, C. & Tschopp, J. Cytolytic T–cell–cytotoxicity is mediated through perforin and Fas ligand pathways. Nature 370, 650–653 (1994).
Article CAS Google Scholar
- Kägi, D. et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin–deficient mice. Nature 369, 31–37 (1994).
Article Google Scholar
- Galle, P.R. et al. Involvement of the CD95 (APO–1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182, 1223– 1230 (1995).
Article CAS Google Scholar
- Kondo, T., Suda, T., Fukuyama, H., Adachi, M. & Nagata, S. Essential roles of the Fas ligand in the development of hepatitis. Nature Med. 3, 409– 413 (1997).
Article CAS Google Scholar
- Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R. & Ferguson, T.A. Fas ligand–induced apoptosis as a mechanism of immune privilege. Science 270, 1189–1192 (1995).
Article CAS Google Scholar
- Bellgrau, D. et al. A role for CD95 ligand in preventing graft rejection. Nature 377, 630–632 (1995).
Article CAS Google Scholar
- French, L.E. et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune–privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell. Biol. 133, 335–343 (1996).
Article CAS Google Scholar
- Hahne, M. et al. Melanoma cell expression of Fas(Apo–1/CD95) ligand: implications for tumor immune escape. Science 274, 1363–1366 (1996).
Article CAS Google Scholar
- Strand, S. et al. Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells—a mechanism of immune evasion? Nature Med. 2, 1361–1366 (1996).
Article CAS Google Scholar
- Matiba, B., Mariani, S.M. & Krammer, P.H. The CD95 system and the death of a lymphocyte. Semin. Immunol. 9, 59–68 (1997).
Article CAS Google Scholar
- Nagata, S. Apoptosis by death factor. Cell 88, 355– 365 (1997).
Article CAS Google Scholar
- Emery, J.G. et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363– 14367 (1998).
Article CAS Google Scholar